148 related articles for article (PubMed ID: 18652752)
1. Detection of 1-benzylpiperazine and 1-(3-trifluoromethylphenyl)-piperazine in urine analysis specimens using GC-MS and LC-ESI-MS.
Vorce SP; Holler JM; Levine B; Past MR
J Anal Toxicol; 2008; 32(6):444-50. PubMed ID: 18652752
[TBL] [Abstract][Full Text] [Related]
2. Development of simultaneous gas chromatography-mass spectrometric and liquid chromatography-electrospray ionization mass spectrometric determination method for the new designer drugs, N-benzylpiperazine (BZP), 1-(3-trifluoromethylphenyl)piperazine (TFMPP) and their main metabolites in urine.
Tsutsumi H; Katagi M; Miki A; Shima N; Kamata T; Nishikawa M; Nakajima K; Tsuchihashi H
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 May; 819(2):315-22. PubMed ID: 15833296
[TBL] [Abstract][Full Text] [Related]
3. Detection of 1-benzylpiperazine, 1-(3-trifluoromethylphenyl)-piperazine, and 1-(3-chlorophenyl)-piperazine in 3,4-methylenedioxymethamphetamine-positive urine samples.
Dickson AJ; Vorce SP; Holler JM; Lyons TP
J Anal Toxicol; 2010 Oct; 34(8):464-9. PubMed ID: 21819791
[TBL] [Abstract][Full Text] [Related]
4. New designer drug 1-(3-trifluoromethylphenyl) piperazine (TFMPP): gas chromatography/mass spectrometry and liquid chromatography/mass spectrometry studies on its phase I and II metabolism and on its toxicological detection in rat urine.
Staack RF; Fritschi G; Maurer HH
J Mass Spectrom; 2003 Sep; 38(9):971-81. PubMed ID: 14505325
[TBL] [Abstract][Full Text] [Related]
5. Isolation, identification and excretion profile of the principal urinary metabolite of the recently banned designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP) in rats.
Tsutsumi H; Katagi M; Miki A; Shima N; Kamata T; Nakajima K; Inoue H; Kishi T; Tsuchihashi H
Xenobiotica; 2005 Jan; 35(1):107-16. PubMed ID: 15788372
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the first deaths in the United Kingdom involving the detection and quantitation of the piperazines BZP and 3-TFMPP.
Elliott S; Smith C
J Anal Toxicol; 2008 Mar; 32(2):172-7. PubMed ID: 18334102
[TBL] [Abstract][Full Text] [Related]
7. Biochip array technology immunoassay performance and quantitative confirmation of designer piperazines for urine workplace drug testing.
Castaneto MS; Barnes AJ; Concheiro M; Klette KL; Martin TA; Huestis MA
Anal Bioanal Chem; 2015 Jun; 407(16):4639-48. PubMed ID: 25903022
[TBL] [Abstract][Full Text] [Related]
8. Studies on the metabolism and toxicological detection of the new designer drug N-benzylpiperazine in urine using gas chromatography-mass spectrometry.
Staack RF; Fritschi G; Maurer HH
J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Jun; 773(1):35-46. PubMed ID: 12015268
[TBL] [Abstract][Full Text] [Related]
9. In vitro hepatotoxicity of 'Legal X': the combination of 1-benzylpiperazine (BZP) and 1-(m-trifluoromethylphenyl)piperazine (TFMPP) triggers oxidative stress, mitochondrial impairment and apoptosis.
Dias da Silva D; Silva MJ; Moreira P; Martins MJ; Valente MJ; Carvalho F; Bastos ML; Carmo H
Arch Toxicol; 2017 Mar; 91(3):1413-1430. PubMed ID: 27358233
[TBL] [Abstract][Full Text] [Related]
10. Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl) piperazine (TFMPP) and 1-benzylpiperzine (BZP).
Wood DM; Button J; Lidder S; Ramsey J; Holt DW; Dargan PI
J Med Toxicol; 2008 Dec; 4(4):254-7. PubMed ID: 19031377
[TBL] [Abstract][Full Text] [Related]
11. Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry.
Peters FT; Schaefer S; Staack RF; Kraemer T; Maurer HH
J Mass Spectrom; 2003 Jun; 38(6):659-76. PubMed ID: 12827635
[TBL] [Abstract][Full Text] [Related]
12. Metabolism and the urinary excretion profile of the recently scheduled designer drug N-Benzylpiperazine (BZP) in the rat.
Tsutsumi H; Katagi M; Miki A; Shima N; Kamata T; Nakajima K; Inoue H; Kishi T; Tsuchihashi H
J Anal Toxicol; 2006; 30(1):38-43. PubMed ID: 16620530
[TBL] [Abstract][Full Text] [Related]
13. Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market.
de Boer D; Bosman IJ; Hidvégi E; Manzoni C; Benkö AA; dos Reys LJ; Maes RA
Forensic Sci Int; 2001 Sep; 121(1-2):47-56. PubMed ID: 11516887
[TBL] [Abstract][Full Text] [Related]
14. [1-benzylpiperazine (BZP) and 1-(3-trifluorométhylphényl)pipérazine (TFMPP): emergence of two agents which lead to misuse].
Lecompte Y; Roussel O; Perrin M
Ann Pharm Fr; 2008 Mar; 66(2):85-91. PubMed ID: 18570904
[TBL] [Abstract][Full Text] [Related]
15. Role of liquid chromatography-high-resolution mass spectrometry (LC-HR/MS) in clinical toxicology.
Wu AH; Gerona R; Armenian P; French D; Petrie M; Lynch KL
Clin Toxicol (Phila); 2012 Sep; 50(8):733-42. PubMed ID: 22888997
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of 'party pill' drug N-benzylpiperazine (BZP) in healthy human participants.
Antia U; Lee HS; Kydd RR; Tingle MD; Russell BR
Forensic Sci Int; 2009 Apr; 186(1-3):63-7. PubMed ID: 19261399
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of new psychoactive substances: A retrospective study in hair.
Rust KY; Baumgartner MR; Dally AM; Kraemer T
Drug Test Anal; 2012 Jun; 4(6):402-8. PubMed ID: 22522922
[TBL] [Abstract][Full Text] [Related]
18. Determination of estrogens and progestogens by mass spectrometric techniques (GC/MS, LC/MS and LC/MS/MS).
Díaz-Cruz MS; López de Alda MJ; López R; Barceló D
J Mass Spectrom; 2003 Sep; 38(9):917-23. PubMed ID: 14505318
[TBL] [Abstract][Full Text] [Related]
19. Validation of an LC-MS method for the detection and quantification of BZP and TFMPP and their hydroxylated metabolites in human plasma and its application to the pharmacokinetic study of TFMPP in humans.
Antia U; Tingle MD; Russell BR
J Forensic Sci; 2010 Sep; 55(5):1311-8. PubMed ID: 20533987
[TBL] [Abstract][Full Text] [Related]
20. Toxicological detection of the new designer drug 1-(4-methoxyphenyl)piperazine and its metabolites in urine and differentiation from an intake of structurally related medicaments using gas chromatography-mass spectrometry.
Staack RF; Maurer HH
J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Dec; 798(2):333-42. PubMed ID: 14643514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
